This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lowenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.
Cannistra SA, Groshek P, Griffin JD . Granulocyte–macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989; 3: 328–334.
van Oijen MG, Medema RH, Slootweg PJ, Rijksen G . Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol 1998; 110: 24–31.
Jedema I, Barge RM, Willemze R, Falkenburg JH . High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G(1) phase of the cell cycle and can be increased by interferon treatment. Leukemia 2003; 17: 576–584.
Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE . Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302–1311.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jedema, I., Barge, R., Nijmeijer, B. et al. Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin. Leukemia 17, 2049–2051 (2003). https://doi.org/10.1038/sj.leu.2403085
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403085
This article is cited by
-
B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells
Journal of Neuro-Oncology (2008)
-
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity
Leukemia (2004)